Literature DB >> 1555036

The work of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT)

J S Smolen.   

Abstract

Mesh：

Year:  1992        PMID： 1555036     DOI： 10.1093/rheumatology/31.4.219

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN： 0263-7103


× No keyword cloud information.
  6 in total

1.  The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

2.  Patients with rheumatoid arthritis in clinical care.

Authors:  J S Smolen; D Aletaha
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

3.  Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.

Authors:  V P K Nell; K P Machold; T A Stamm; G Eberl; H Heinzl; M Uffmann; J S Smolen; G Steiner
Journal:  Ann Rheum Dis       Date:  2005-05-05       Impact factor: 19.103

4.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.

Authors:  Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen
Journal:  Arthritis Res Ther       Date:  2005-04-07       Impact factor: 5.156

5.  Reliability and validity of CDAI and SDAI indices in comparison to DAS-28 index in Moroccan patients with rheumatoid arthritis.

Authors:  Imane Ben Slama; Fadoua Allali; Touria Lakhdar; Sarra El Kabbaj; Lamyae Medrare; Ange Ngeuleu; Hanan Rkain; Najia Hajjaj-Hassouni
Journal:  BMC Musculoskelet Disord       Date:  2015-09-29       Impact factor: 2.362

6.  The added value of musculoskeletal ultrasound to clinical evaluation in the treatment decision of rheumatoid arthritis outpatients: physician experience matters.

Authors:  C Sifuentes-Cantú; I Contreras-Yáñez; L Saldarriaga; A C Lozada; M Gutiérrez; V Pascual-Ramos
Journal:  BMC Musculoskelet Disord       Date:  2017-09-11       Impact factor: 2.362
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.